Talphera
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 15
- Market Cap
- $16.4M
- Introduction
Talphera, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The firm's portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in San Mateo, CA.
Effect of Delivery Route on PK of Sufentanil NanoTab
- Conditions
- First Posted Date
- 2012-07-13
- Last Posted Date
- 2015-10-01
- Lead Sponsor
- Talphera, Inc
- Target Recruit Count
- 25
- Registration Number
- NCT01639729
- Locations
- 🇺🇸
PRA, Lenexa, Kansas, United States
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalvisoâ„¢) for the Treatment of Post-Operative Pain in Patients After Open Abdominal Surgery
- Conditions
- Interventions
- First Posted Date
- 2012-02-27
- Last Posted Date
- 2015-10-20
- Lead Sponsor
- Talphera, Inc
- Target Recruit Count
- 172
- Registration Number
- NCT01539642
- Locations
- 🇺🇸
G&G Research, Vero Beach, Florida, United States
🇺🇸Surgical Associates of Mobile, Mobile, Alabama, United States
🇺🇸Caring Clinical Research Corporation, Laguna Hills, California, United States
A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalvisoâ„¢)to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative Pain
- Conditions
- Interventions
- First Posted Date
- 2012-02-27
- Last Posted Date
- 2015-10-01
- Lead Sponsor
- Talphera, Inc
- Target Recruit Count
- 357
- Registration Number
- NCT01539538
- Locations
- 🇺🇸
Shoals Medical Trials, Inc, Sheffield, Alabama, United States
🇺🇸Florida Research Associates, LLC, DeLand, Florida, United States
🇺🇸Pensacola Research Consultants, Inc, Pensacola, Florida, United States
A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTabâ„¢ in Patients Undergoing an Elective Abdominal Liposuction Procedure
- Conditions
- Interventions
- First Posted Date
- 2009-05-07
- Last Posted Date
- 2014-06-25
- Lead Sponsor
- Talphera, Inc
- Target Recruit Count
- 40
- Registration Number
- NCT00894699
- Locations
- 🇺🇸
Lotus Clinical Research, Inc., Pasadena, California, United States
An Open-Label Functionality, Safety and Efficacy Study in Patients Undergoing Elective Unilateral Knee Replacement
- Conditions
- Interventions
- First Posted Date
- 2009-03-11
- Last Posted Date
- 2012-03-01
- Lead Sponsor
- Talphera, Inc
- Target Recruit Count
- 30
- Registration Number
- NCT00859313
- Locations
- 🇺🇸
West Alabama Research, Inc, Birmingham, Alabama, United States
🇺🇸Memorial Hermann/Memorial City Medical Center, Houston, Texas, United States
🇺🇸Orthopedic Center of Vero Beach, Vero Beach, Florida, United States
A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab) Compared to Placebo in the Treatment of Cancer Breakthrough Pain
- Conditions
- Interventions
- First Posted Date
- 2009-01-30
- Last Posted Date
- 2015-01-01
- Lead Sponsor
- Talphera, Inc
- Target Recruit Count
- 34
- Registration Number
- NCT00833040
- Locations
- 🇺🇸
Clinical Trials and Research Associates, Montebello, California, United States
🇺🇸Drug Studies America, Inc., Marietta, Georgia, United States
🇺🇸Lovelace Scientific Resources, Venice, Florida, United States
A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Major Abdominal Surgery
- Conditions
- Interventions
- First Posted Date
- 2008-07-18
- Last Posted Date
- 2015-01-22
- Lead Sponsor
- Talphera, Inc
- Target Recruit Count
- 88
- Registration Number
- NCT00718081
- Locations
- 🇺🇸
Trio Clinical Research, Durham, North Carolina, United States
A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Elective Unilateral Total Knee Replacement
- Conditions
- Interventions
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2014-02-17
- Lead Sponsor
- Talphera, Inc
- Target Recruit Count
- 94
- Registration Number
- NCT00612534
- Locations
- 🇺🇸
Trio Clinical Research, Durham, North Carolina, United States